Trial Profile
A Phase IIa, Multicenter, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK8245 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs MK 8245 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 19 Jun 2019 This trial has been discontinued in Poland, according to European Clinical Trials Database.
- 10 Mar 2012 Planned number of patients changed from 60 to 76 as reported by European Clinical Trials Database record.
- 03 Jun 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.